390. Lenacapavir Adherence and Effectiveness Over 2 Years of Use in the OPERA Cohort

作者：Karam Mounzer, Laurence Brunet, Ricky K Hsu, Philip C Lackey, Michael Sension, Michael Wohlfeiler, Keith Dunn, Jennifer S Fusco, Gregory Fusco · 发表于：Open Forum Infectious Diseases · 年份：2026 · DOI：10.1093/ofid/ofaf695.128 · 被引用次数：1 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、HIV/AIDS Research and Interventions

Abstract Background The first in class capsid inhibitor lenacapavir (LEN) is a twice yearly set of two injections used with an optimized background regimen for heavily treatment-experienced individuals with multidrug resistant HIV-1 infection. We describe real-world LEN injection adherence and effectiveness in a US cohort. Methods From electronic health records in the OPERA cohort, all ART-experienced adults with HIV starting a LEN-containing regimen between 22DEC2022 and 30SEP2024 were followed through 31DEC2024. Maintenance or achievement of virologic suppression (viral load < 200 copies/mL) over time on LEN was assessed with Kaplan Meier methods among those with viral load(s) measured during follow-up. Adherence to injection windows among individuals with ≥ 2 sets of injections was defined based on the time elapsed since the prior set of injections (early: < 24 weeks, on-time: ≥ 24 to ≤ 28 weeks, late: > 28 weeks). Discontinuation was defined as the absence of injections between the end of the 28 weeks window and study end. Results A total of 116 individuals received ≥ 1 set of LEN injections (median 3 sets over follow-up; IQR: 2, 4). At the first set, 22% were women, and most had moderate to high CD4 cell counts and low viral loads (Table 1). Of the 61% who added LEN to their prior regimen, 51% had no further changes after LEN initiation. The cumulative probability of maintaining suppression throughout follow-up was high (92%; 95% CI: 80, 96) among 69...